Peripheral immune signatures associated with the risk of hepatocarcinogenesis in cirrhotic Egyptian HCV patients before and after treatment with direct-acting antivirals
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Peripheral immune signatures associated with the risk of hepatocarcinogenesis in cirrhotic Egyptian HCV patients before and after treatment with direct-acting antivirals ; volume:21 ; number:1 ; day:15 ; month:11 ; year:2024 ; pages:1-17 ; date:12.2024
Virology journal ; 21, Heft 1 (15.11.2024), 1-17, 12.2024
- Creator
-
El-Shenawy, Reem
Moustafa, Rehab I.
Helmy, Naiera M.
El-Abd, Yasmine S.
Tabll, Ashraf A.
Elesnawy, Yasser K.
Shawky, Heba
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12985-024-02551-3
- URN
-
urn:nbn:de:101:1-2502242112060.320095952121
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:21 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- El-Shenawy, Reem
- Moustafa, Rehab I.
- Helmy, Naiera M.
- El-Abd, Yasmine S.
- Tabll, Ashraf A.
- Elesnawy, Yasser K.
- Shawky, Heba
- SpringerLink (Online service)
Other Objects (12)
Correction: Peripheral immune signatures associated with the risk of hepatocarcinogenesis in cirrhotic Egyptian HCV patients before and after treatment with direct-acting antivirals
Direct-acting antivirals and visceral leishmaniasis: a case report
Long term changes in thrombocytopenia and leucopenia after HCV eradication with direct-acting antivirals
Drug–Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications
Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway
Simple new clinical score to predict hepatocellular carcinoma after sustained viral response with direct-acting antivirals
Effect of direct-acting antivirals on elastographic measures in patients with chronic hepatitis C virus infection
A systematic review of sofosbuvir/velpatasvir/voxilaprevir in HCV patients previously treated with direct-acting antivirals
Serum autotaxin levels in responders to HCV treatment by direct-acting antivirals
Hepatitis C clearance by direct-acting antivirals impacts glucose and lipid homeostasis
Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease
Simple Predictive Markers and Clinicopathological Features of Primary Liver Cancer following HCV Clearance with Direct-Acting Antivirals
Correction: Peripheral immune signatures associated with the risk of hepatocarcinogenesis in cirrhotic Egyptian HCV patients before and after treatment with direct-acting antivirals
Direct-acting antivirals and visceral leishmaniasis: a case report
Long term changes in thrombocytopenia and leucopenia after HCV eradication with direct-acting antivirals
Drug–Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications
Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway
Simple new clinical score to predict hepatocellular carcinoma after sustained viral response with direct-acting antivirals
Effect of direct-acting antivirals on elastographic measures in patients with chronic hepatitis C virus infection
A systematic review of sofosbuvir/velpatasvir/voxilaprevir in HCV patients previously treated with direct-acting antivirals
Serum autotaxin levels in responders to HCV treatment by direct-acting antivirals
Hepatitis C clearance by direct-acting antivirals impacts glucose and lipid homeostasis
Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease
Simple Predictive Markers and Clinicopathological Features of Primary Liver Cancer following HCV Clearance with Direct-Acting Antivirals
Correction: Peripheral immune signatures associated with the risk of hepatocarcinogenesis in cirrhotic Egyptian HCV patients before and after treatment with direct-acting antivirals
Direct-acting antivirals and visceral leishmaniasis: a case report
Long term changes in thrombocytopenia and leucopenia after HCV eradication with direct-acting antivirals
Drug–Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications
Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway
Simple new clinical score to predict hepatocellular carcinoma after sustained viral response with direct-acting antivirals
Effect of direct-acting antivirals on elastographic measures in patients with chronic hepatitis C virus infection
A systematic review of sofosbuvir/velpatasvir/voxilaprevir in HCV patients previously treated with direct-acting antivirals
Serum autotaxin levels in responders to HCV treatment by direct-acting antivirals
Hepatitis C clearance by direct-acting antivirals impacts glucose and lipid homeostasis
Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease